阿利西尤单抗降低脂蛋白(a)独立于低密度脂蛋白胆固醇降低减少心血管事件总负担:ODYSSEY OUTCOMES试验
在近期急性冠脉综合征患者中,本事后分析探讨基线脂蛋白(a)及阿利西尤单抗诱导的脂蛋白(a)变化是否独立预测心血管事件总负担。结果显示基线脂蛋白(a)预测安慰剂组总事件,且阿利西尤单抗降低脂蛋白(a)独立于校正LDL-C降低与总事件风险降低相关,支持脂蛋白(a)作为ACS后治疗靶点。
要点
- 基线脂蛋白(a)水平预测安慰剂组心血管事件总负担。
- 阿利西尤单抗诱导的脂蛋白(a)降低独立预测总心血管事件风险降低。
- 脂蛋白(a)每降低5 mg/dL,心血管事件相对风险降低2.5%。
核心结论
- 基线脂蛋白(a)预测心血管事件总负担及阿利西尤单抗的风险降低效应,脂蛋白(a)降低独立贡献于事件减少,支持其作为ACS后治疗靶点。
研究设计与样本
- ODYSSEY OUTCOMES试验的事后分析,纳入近期急性冠脉综合征患者,比较阿利西尤单抗与安慰剂。
主要发现
- 基线脂蛋白(a)预测安慰剂组总心血管事件,基线脂蛋白(a)较高者阿利西尤单抗降低总事件更显著(风险比Ptrend=0.045)。
- 阿利西尤单抗诱导的脂蛋白(a)中位降低-5.0(-13.6, 0)mg/dL,校正LDL-C中位降低-51.3(-67.1, -34.0)mg/dL,二者独立预测总事件风险降低。
- 脂蛋白(a)每降低5 mg/dL,心血管事件相对风险降低2.5%。
临床怎么用
- 在近期ACS患者中,可考虑将脂蛋白(a)作为残余风险标志及潜在治疗靶点,阿利西尤单抗降低脂蛋白(a)带来额外心血管获益。
局限性
- 为事后分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduced lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and cardiovascular events compared with placebo. This post hoc analysis determined whether baseline levels and alirocumab-induced changes in lipoprotein(a) and LDL-C [corrected for lipoprotein(a) cholesterol] independently predicted total cardiovascular events. METHODS AND RESULTS: Cardiovascular events included cardiovascular death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina or heart failure, ischaemia-driven coronary revascularization, peripheral artery disease events, and venous thromboembolism. Proportional hazards models estimated relationships between baseline lipoprotein(a) and total cardiovascular events in the placebo group, effects of alirocumab treatment on total cardiovascular events by baseline lipoprotein(a), and relationships between lipoprotein(a) reduction with alirocumab and subsequent risk of total cardiovascular events. Baseline lipoprotein(a) predicted total cardiovascular events with placebo, while higher baseline lipoprotein(a) levels were associated with greater reduction in total cardiovascular events with alirocumab (hazard ratio Ptrend = 0.045). Alirocumab-induced reductions in lipoprotein(a) (median -5.0 [-13.6, 0] mg/dL) and corrected LDL-C (median -51.3 [-67.1, -34.0] mg/dL) independently predicted lower risk of total cardiovascular events. Each 5-mg/dL reduction in lipoprotein(a) predicted a 2.5% relative reduction in cardiovascular events. CONCLUSION: Baseline lipoprotein(a) predicted the risk of total cardiovascular events and risk reduction by alirocumab. Lipoprotein(a) lowering contributed independently to cardiovascular event reduction, supporting the concept of lipoprotein(a) as a treatment target after ACS.
引用
- Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020. PMID: 33051646. doi:10.1093/eurheartj/ehaa649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。